Research Article
Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro
Table 3
Raw data of Metadichol cytotoxicity in viral absence, as measured by using the neutral red assay. Units are μg/mL unless noted.
| | Metadichol (μg/mL) | Adenovirus | Tacaribe | Rift valley | SARS | Japanese encephalitis | West Nile virus | Yellow fever Powassan virus |
| | 500 | 95% | 98% | 96% | 96% | 100% | 100% | 100% | 100% | | 160 | 92% | 98% | 96% | 95% | 100% | 100% | 100% | 100% | | 50 | 90% | 97% | 97% | 95% | 100% | 100% | 100% | 100% | | 16 | 85% | 95% | 81% | 92% | 88% | 77% | 98% | 100% | | 5 | 0% | 23% | 26% | 35% | 33% | 28% | 35% | 44% | | 1.6 | 0% | 2% | 10% | 15% | 12% | 14% | 19% | 6% | | 0.5 | 0% | 3% | 9% | 0% | 2% | 3% | 2% | 0% | | 0.16 | 0% | 17% | 3% | 0% | 0% | 0% | 4% | 0% | | CC50 | 9.90 | 7.30 | 8.40 | 6.70 | 7.20 | 8.50 | 5.00 | 5.1 |
|
|
CC50: 50% cytotoxic concentration of compound without virus added.
|
